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Abstract
Background: There are currently few effective drugs to treat the leg symptoms of peripheral arterial disease (PAD). Previous studies
have suggested that the nutraceutical, quercetin, can improve exercise performance and reduce pain sensitivity in healthy mice and
improve blood supply in a rodent model of acute hind-limb ischaemia. These models may not be relevant to people with PAD. The
aim of this study was to examine the effect of quercetin on exercise performance, physical activity and blood supply in a novel
mouse model of sustained hind-limb ischaemia.
Methods: Hind-limb ischaemia was induced in 6-month-old male apolipoprotein E-deficient mice using a novel two-stage surgical
procedure. Five days after induction of ischaemia, mice were allocated to commence dietary quercetin or a control diet for 4 weeks.
The primary outcome was exercise performance evaluated using a treadmill test. Other outcomes included physical activity,
estimated by an open field test, and hind-limb blood supply, assessed by laser Doppler monitoring.
Results: A sustained reduction in relative limb blood supply (P< 0.001) was achieved consistently in all 48 mice before allocation to a
control (n¼ 24) or quercetin (n¼ 24) diet. Quercetin did not improve exercise performance (P¼ 0.785), physical activity (P¼ 0.151) or
relative limb blood supply (P¼ 0.954) over the 4-week assessment period.
Conclusion: These data suggest that quercetin does not improve exercise performance, physical activity or limb blood supply in
mice with sustained hind-limb ischaemia, and therefore is unlikely be an effective treatment for PAD.
Surgical relevance
This paper describes the testing of a nutriceutical in a novel pa-
tient-relevant model of limb ischaemia. The study suggests that
quercetin did not improve limb ischemia or ambulation ability in
this clinically relevant model.
Presented as a poster to the Australian Vascular Biology Society
Meeting, Sydney, New South Wales, Australia, September 2019
Introduction
Peripheral arterial disease (PAD) is a common cause of leg pain,
walking impairment, low physical activity. and poor health-related
quality of life1–3. Cilostazol is the only currently available drug ther-
apy for the leg symptoms of PAD, but is not commonly used or cur-
rently recommended by European practice guidelines4.
The flavonoids are a group of polyphenols found in some
foods5. Previous reports have suggested that the flavonoid quer-
cetin can improve recovery of limb blood flow and increase
capillary density6, reduce muscle atrophy7,8, and limit oxidative
stress and reduce proinflammatory cytokine concentrations in
skeletal muscle9,10 in animal models. Cytokines, including inter-
leukin (IL) 6 and tumour necrosis factor (TNF) a, have been
detected at high levels in the skeletal muscle of patients with
PAD11. High concentrations of these cytokines and low availabil-
ity of nitric oxide have been suggested to contribute to the most
common and debilitating symptoms of PAD: poor ambulatory
performance12 and muscle pain11. Quercetin has been reported
to improve exercise performance in healthy mice13 and to reduce
acid-induced pain stimulation9. This is potentially achieved
through a reduction of TNF-a and increases in endothelial nitric
oxide production6. These research findings suggest that quercetin
may be an effective treatment for PAD; however, the relevance of
these previous studies to people with PAD is unclear.
Previous animal studies on PAD have a number of limitations,
including the use of an acute ischaemia model in which blood
supply recovers rapidly, investigating young rodent strains with
excellent angiogenesis ability, poor study design, and employing
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outcome measures unrepresentative of the clinical situation, as
reviewed in detail previously14. A novel two-stage surgical hind-
limb ischaemia (HLI) mouse model was developed previously to
simulate human PAD better15. This two-stage model has
sustained HLI without spontaneous recovery, and also illustrates
impaired exercise performance15. The aim of this study was to
test the effect of quercetin supplementation on exercise perfor-
mance, physical activity and blood supply in the two-stage HLI
rodent model.
Methods
Male apolipoprotein E-deficient (ApoE/) mice aged 18–22 weeks
were purchased from the Animal Resources Centre (Canning Vale,
WA, Australia) and acclimatized for 4 weeks at the animal facility
at James Cook University. Mice were housed, one per cage, in indi-
vidually ventilated techniplast cages with corn cob bedding, on a
12/12-h light/dark cycle, at a relative humidity of 556 2 per cent
and a temperature of 23 6 2C. Before experiments, mice were
maintained on normal laboratory chow and water ad libitum. All
conditions were kept constant between experimental groups, with
the exception of quercetin being incorporated into the diet of the in-
tervention group. Ethics approval was obtained from the James
Cook University Animal Ethics Committee (A2352). Mice were moni-
tored twice-daily after surgery.
Study design and outcome assessment
Unilateral HLI was induced in 22–26-week-old mice through two se-
quential operations on days 1 and 14 after the start of the experi-
ment, as described previously15. Mice were then allocated to two
experimental groups with similar mean baseline exercise perfor-
mance and similar levels of ischaemia, as indicated by
laser Doppler blood flow measurements on postoperative day 14.
Animals in group 1 received a diet that contained quercetin, and
those in group 2 received an otherwise identical control diet that
did not contain quercetin. Mice were allowed to recover from sur-
gery, and 5 days later, on day 19, were fed either the diet containing
quercetin or the control diet until the end of the experiment (day
51). Research was conducted in accordance with the Animal
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines16.
Exercise performance was assessed in a treadmill test (TMT),
performed at baseline (day 0) and on days 24, 34 and 44 after the
start of the experiment. Physical activity was monitored through
open field tests performed on day 44, and limb pressure sensitiv-
ity was assessed on day 48. Hind-limb blood flow was measured
on days 0, 13, 15, 28, 35 and 49 (Fig. S1). Blood samples were taken
from the tail vein on days 0, 30 and 51 (endpoint). Bodyweight
was measured weekly. At the end of the experiments, mice were
killed by carbon dioxide asphyxiation.
Induction of sustained hind-limb ischaemia
Unilateral HLI was created with a two-stage surgical procedure,
as described in detail previously15. Briefly, in the first operation
two hygroscopic ameroid constrictors with an internal diameter
of 0.25 mm (Research Instruments SW, Escondido, CA, USA) were
placed around the femoral artery, one inferior to the internal iliac
artery branch and one superior to the deep femoral artery
branch. Fourteen days later, the femoral artery was ligated using
6/0 silk sutures at two sites, one adjacent to each ameroid con-
strictor, and the artery was resected along with both ameroid
constrictors and any adherent collateral branches. The incisions
were closed and animals were monitored for recovery.
Experimental groups
Control mice received a diet containing 20 per cent protein,
4.8 per cent fat, 4.8 per cent crude fibre, 0.8 per cent calcium,
0.7 per cent phosphorous, 0.36 per cent salt, and 14-MJ/kg digest-
ible energy (Specialty Feeds, Glen Forrest, WA, Australia). The
intervention group received quercetin (Q4951; Sigma, Castle Hill,
NSW, Australia), 0.16 per cent w/w, incorporated into a diet
otherwise identical to the control diet. Based on an average food
consumption of 3.45 g/day17, mice in this study consumed ap-
proximately 185 mg/kg quercetin daily.
Assessment of exercise performance with a
treadmill test
This was the primary outcome for the study. A TMT was per-
formed using a six-lane treadmill (Excer-3/6; Columbus
Instruments, Port Macquarie, NSW, Australia), as described
previously15. The test measured distance travelled to fatigue,
comparable with maximum walking distance commonly mea-
sured in clinical trials15,18. Mice were acclimatized to the tread-
mill over a 3-day period for 15 min each day before experiments
took place. Before each TMT, mice were fasted for 2 h to avoid
postprandial effects. Over the first minute, the speed was
increased to 15 m/min and shock grids were turned on. Total
distance travelled was recorded from the start of running at
10 m/min, and mice were considered fatigued once they had
10 separate visits to the shock grid.
Assessment of physical activity with an open
field test
The open field test measured voluntary activity and has been
compared to a 6-min walk test used in clinical trials, although it
is more relatable to an objective measure of physical activity
such as an accelerometer19. Mice were acclimatized in the build-
ing where open field experiments had occurred 3 days before re-
cording. The animals were placed in an open field cube
(40 40 40 cm, divided into an outer field and a central field of
20 20 cm), and their movement was recorded for 20 min with a
Logitech quick capture webcamVR (Logitech Australia Computer
Peripherals Pty Ltd, Marleston, South Australia). Analyses of open
field recordings were performed using TopScan Lite 2.0 software.
Total distance travelled and total velocity were recorded for each
mouse, to allow for comparison between groups.
Assessment of hind-limb pressure sensitivity
Limb pressure sensitivity was measured using a pressure applica-
tion device (PAM) (Ugo Basile, Gemonio, Italy), as reported previ-
ously15. Limb pressure sensitivity is a model of induced pain
response that has been used to assess pain due to ischaemia20.
Mice were restrained in a supine position and pressure was ap-
plied to the hind limb with a force transducer at a rate of 20 g/s.
The point at which mice withdrew the limb, vocalized, or had
twitching of whiskers in response to the device was considered
the endpoint. The peak force applied immediately before the end-
point was considered the limb withdrawal threshold. The data
were normalized as the limb withdrawal threshold ratio of the
left (ischaemic) and right (contralateral) hind limb, to allow com-
parison between groups.
Assessment of blood flow with laser Doppler
perfusion imaging
Blood flow was measured in both hind limbs of mice using laser
Doppler perfusion imaging (LDPI) (Moor Instruments, Axminster,
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UK). Isoflurane (Henry Schein, Columbus, OH, USA) was adminis-
tered at 3 per cent in oxygen at a flow rate of 1 l/min. Hind limbs
were taped with the plantar surface facing downward, and
Doppler imaging was performed. The colour flux image produced
by LDPI was analysed to produce perfusion units using computer
software (MoorLDI version 3.08, Moor Instruments, Axminster,
UK). These perfusion units were then normalized as left to right
hind-limb ratios to allow comparison between groups. The coeffi-
cient of variation of intraobserver and interobserver
reproducibility of measurements of limb perfusion were
3.5 per cent (n¼ 43) and 5.1 per cent (n¼ 43) respectively.
Preparation of plasma samples
Blood samples were centrifuged at 4C, 2000g for 10 min, and
supernatant was transferred to microfuge tubes for further
centrifugation at 15 000g for 10 min. Supernatant plasma was
aliquoted into microfuge tubes, snap-frozen in liquid nitrogen,
and stored in 80C freezers.
Total plasma nitrate and nitrite concentration
Total nitrate and nitrite concentrations were quantified in the
plasma as a measure of nitric oxide concentration. Analysis was
performed on plasma samples collected from mice at baseline
and day 30 after the start of the experiment using a nitric oxide
fluorometric assay kit (ab65327; Abcam, Melbourne VIC,
Australia) according to the instructions for use. Fluorescence was
measured at an excitation and emission of 360 and 450 nm, and
converted to millimolar concentrations using a standard curve.
Quantification of plasma cytokines
Plasma IL-6, IL-10, IL-12 and TNF-a concentrations were mea-
sured at baseline and endpoint using a cytokine magnetic bead
panel (MILLIPLEXVR , MCYTOMAG-70KVR , Melbourne, Australia)
according to instructions for use. Briefly, 25-ml plasma samples
were incubated overnight to allow for binding of cytokines to
bead antibodies. Samples were incubated with detection antibod-
ies and streptavidin–phycoerythrin, and the plate was run on a
MAGPIXVR machine (Abacus dx, Meadowbrook, QLD, Australia).
Concentrations were converted to picograms per millilitre using a
standard curve.
Sample size calculation
The required sample size was calculated based on the effect size
reported for quercetin improving exercise performance in a TMT
in healthy mice13. In that study, 16 mice were given quercetin
(25 mg/kg daily) for 7 days and achieved a mean(s.e.m.) of 37(9.5)
per cent longer distance during the test than controls13. The sam-
ple size calculation for the present study was two-tailed; power
was set to 0.80 and the a value was set at 0.05. Based on these val-
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Fig. 1 Effect of quercetin on ambulatory performance, pressure sensitivity and voluntary activity
a Distance travelled in a treadmill test. 1, surgical procedure to implant ameroid constrictors; 2, surgical procedure to ligate femoral artery and establish hind-limb
ischaemia. Data were analysed using a linear mixed-effects model, and were log-transformed during statistical analysis to conform to model assumptions,
although raw values are shown here. Log-transformation of the data did not change statistical findings from the primary analysis. Values are mean(s.e.m.). b Force
applied to hind-limb paws immediately before limb withdrawal or signs of distress, expressed as a ratio of left (ischaemic) to right (contralateral) limb. Median
values, interquartile ranges and ranges are denoted by horizontal bars, boxes and error bars respectively. c The mean(s.e.m.) velocity at which mice moved during
an open field test in the whole area, and specifically within the exterior and centre zones. d Mean(s.e.m.) distance travelled during an open field test in the whole
area, and specifically within exterior and centre zones. There were 23 animals in the quercetin group and 22 control animals. For P values, see main text.
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Sample size was increased by 20 per cent to account for potential
dropouts due to surgical complications or mice welfare concerns.
Statistical analysis
Data were tested for gaussian distribution using the D’Agostino
and Pearson test. Normally distributed data were expressed as
mean(s.e.m.) values, and non-normally distributed data as
median (i.q.r.) values. Differences between groups were assessed
using unpaired two-tailed t tests or Mann–Whitney U tests, as
appropriate. Plasma cytokine values that did not fall within the
assay detection range were excluded. Blood flow, distance trav-
elled and bodyweight were measured at multiple time points
throughout the study, and compared between groups using linear
mixed-effects models. Blood flow, distance travelled, or body-
weight and time were set as fixed effects, and variation between
individual mice was set as a random effect. The interaction
of time and treatment was considered in order to assess
significance in these tests. Mice were allocated to control or
quercetin-enriched diet 5 days after the second HLI operation;
however, data for the individual groups of mice are presented
and analysed from the start of the experiment (before HLI induc-
tion) to illustrate the overall effect of ischaemia on outcomes.
Model fit was assessed through examination of the spread of
standardized residuals and normal Q-Q diagnostic plots. Where
diagnostic plots suggested that the assumptions of linear mixed
effects were not met, data were log-transformed. Where poten-
tially influential outliers were identified (defined as more than 3
standard deviations from the mean of all residuals for linear
mixed-effects models), sensitivity analyses were conducted
excluding these outliers. Differences were considered statistically
significant when P < 0.050. Statistical analyses were performed
using GraphPad PrismVR version 6 (GraphPad Software, San Diego,
CA, USA) and RStudio (https://rstudio.com).
Results
A total of 48 mice commenced the experiment, 24 mice per group.
Three mice (one from the intervention group and two controls)
did not wake up from anaesthesia following HLI induction, and
were excluded from the study as the intervention had not com-
menced. Bodyweight of mice did not change significantly over
the duration of the experiment and was similar in both groups
(Fig. S2). The exclusion of outliers identified in bodyweight data
did not affect the statistical findings.
The mean(s.e.m.) distance travelled during the TMT increased
significantly over time in mice allocated to control (117.6(24.8),
187.1(39.0), 283.3(43.5), 353.8(59.3)) and quercetin (147.7(35.0),
270.0(50.1), 422.6(96.3), 310.3(46.9)) diets on days 0, 24, 34 and
44 respectively (P< 0.001) (Fig. 1a), but there was no difference
































Time after surgery (days)
















































































Fig. 2 Effect of quercetin on hind-limb perfusion measured by laser Doppler perfusion imaging and plasma nitrate and nitrite concentrations
a Hind-limb perfusion decreased after surgery in both groups, but did not differ between groups (quercetin, n¼23; controls, n¼22). 1, surgical procedure to implant
ameroid constrictors; 2, surgical procedure to ligate femoral artery and establish hind-limb ischaemia. Data presented as mean(s.e.m.) values and analysed using a
linear mixed-effects model. b Representative laser Doppler perfusion (LDP) images of hind-limb perfusion at baseline and day 28. c Median (i.q.r.) total plasma
nitrate and nitrite concentrations did not differ between groups at baseline (quercetin, n¼ 12; controls, n¼12). d Median (i.q.r.) total plasma nitrate and nitrite
concentrations were significantly higher in mice consuming quercetin on day 30 (quercetin, n¼ 12; controls, n¼12). c,d Median values, interquartile ranges and
ranges are denoted by horizontal bars, boxes and error bars respectively. *P ¼ 0.021 (Mann–Whitney U test). For P values, see main text.
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no significant difference in the ratio of withdrawal force after
pressure application between control (median 0.8 (i.q.r. 0.6–1.2))
and quercetin (0.9 (0.6–1.2)) groups on day 48 (P¼ 0.866.
Mann–Whitney U test) (Fig. 1b),. Mean(s.e.m.) velocity (43.3(1.9)
versus 45.4(1.8) mm/s; P¼ 0.412, unpaired 2-tailed t test) and dis-
tance travelled (42.8(2.1) versus 47.0(1.9) mm; P¼ 0.151, unpaired
2-tailed t test) in an open field test were also not significantly dif-
ferent between control and quercetin groups on day 44 (Fig. 1c,d).
Hind-limb perfusion ratios decreased following the two-stage
HLI model compared with baseline in mice subsequently allo-
cated control (mean(s.e.m.) 1.03(0.04) versus 0.55(0.02)) or querce-
tin (1.05(0.04) versus 0.57(0.03)) diets (P< 0.001). The degree of HLI
did not significantly differ between mice allocated control
(0.42(0.02), 0.49(0.03), 0.43(0.03)) and quercetin (0.40(0.03),
0.45(0.03), 0.41(0.03)) diets on days 28, 35 and 49 (P¼ 0.954)
(Fig. 2a,b). Total plasma nitrate and nitrite concentration was not
significantly different between mice allocated control (median
196.6 (i.q.r. 70.4–359.4) mmol/l) and quercetin (92.3 (32.5–326.8)
mmol/l) diets on day 0 (P¼ 0.272, Mann–Whitney U test) (Fig. 2c).
Mice that consumed quercetin had significantly greater total
plasma nitrate and nitrite concentrations than controls 30 days
after surgery (173.4 (104.9–195.7) versus 94.6 (51.5–127.2) mmol/l;
P¼ 0.021, Mann–Whitney U test) (Fig. 2d).
There was no significant difference between control and querce-
tin groups at the study endpoint in plasma TNF-a (median 5.6 (i.q.r.
2.6–8.6) versus 8.0 (3.3–14.4) pg/ml respectively; P¼ 0.619, Mann–
Whitney U test), IL-6 (54.9 (41.2–100.2) versus 75.5 (45.8–139.6) pg/
ml; P¼ 0.565, Mann–Whitney U test), IL-10 (6.4 (3.3–125.8) versus
18.9 (6.5–36.4) pg/ml; P¼ 0.704, Mann–Whitney U test) or IL-12 (54.6
(3.4–118.6) versus 19.3 (8.6–52.3) pg/ml; P¼ 0.724, Mann–Whitney U
test) (Fig. 3).
Discussion
This study found that administration of quercetin after induction
of HLI did not improve exercise performance or increase physical
activity in a mouse model designed to simulate the physical per-
formance impairment caused by PAD. It was reported previously6
that administration of isoquercitrin conjugated to glucose moie-
ties (a form of bioavailable quercetin) to mice improved hind-
limb blood supply when started 2 weeks before induction of acute
HLI. Conversely, the present study found that administration of
quercetin after HLI induction did not improve limb perfusion.
Previous mouse studies7,13,21–24 reported that a dose of
185 mg/kg daily of quercetin, as used in the present study, was
effective at improving exercise performance, reducing muscle
atrophy, and reducing inflammation. This dose was also esti-
mated to equate to 1000 mg/day in human subjects based on
body surface area calculations25. A dose of 1000 mg/day has been


























































Fig. 3 Plasma cytokine concentrations at baseline before induction of hind-limb ischaemia or quercetin administration and at the endpoint after
4 weeks of quercetin
a Plasma interleukin (IL) 6, b IL-10, c IL-12, and d tumour necrosis factor (TNF) a concentrations. Values are median (i.q.r.). Median values, interquartile ranges and
ranges are denoted by horizontal bars, boxes and error bars respectively. For P values, see main text.









niversity user on 24 M
arch 2021
side-effects, and beneficial effects on exercise performance in
healthy subjects have been reported at this dose26,27. In the pre-
sent study, administration of quercetin increased total plasma
nitrates (an indicator of nitric oxide), suggesting the dose of quer-
cetin was adequate. Nitric oxide has been critically implicated in
improving blood flow and increasing angiogenesis, and is the
suggested mechanism by which quercetin has improved hind-
limb blood supply in previous studies6. Based on these data,
quercetin would be expected to promote angiogenesis and
thus limb blood supply, but in the present study quercetin had
no effect on limb perfusion.
This study used old mice that had dyslipidaemia and
sustained HLI in order to model human PAD. Old mice are less
responsive to interventions that stimulate arteriogenesis, angio-
genesis, and mitochondrial biogenesis28. The two-stage surgical
model used in the present study also limits changes in shear
stress due to gradual occlusion, and limits the collateral circula-
tion that usually forms quickly after acute HLI14,29. This may
explain why quercetin did not improve exercise performance and
blood flow in the present study, in contrast to previously reported
studies utilizing other mouse models13.
Limb pain is a common symptom in patients with PAD, but
difficult to assess in animal models. Quercetin has been reported
previously9 to reduce pain from acetic acid injection; however,
the effects of quercetin on pain have not been evaluated previ-
ously in HLI models. The present study assessed the effects of
quercetin on hind-limb hypersensitivity to mechanical pressure
and found no effect. Furthermore, quercetin administered in the
diet did not appear to alter plasma IL-6, IL-10, IL-12 or TNF-a con-
centrations, although the sample sizes were small for these com-
parisons. The findings suggest that quercetin is unlikely to be
beneficial for pain secondary to ischaemia.
This study had a number of strengths and limitations.
Strengths were the inclusion of key design features, such as ade-
quate sample sizes and use of a clinically relevant model.
Quercetin was added to the diet to mimic human consumption
through the diet as opposed to direct administration through ga-
vage. Bodyweight data suggested that mice in both groups con-
sumed diet equally. Supplementation may be modelled through
gavage in mice, and this route of administration may have shown
better efficacy. Quercetin was administered after sustained HLI
had been established, in order to reflect what occurs clinically, as
patients seek treatment once symptoms have developed.
Quercetin was tested over a 30-day period, and it is possible that
a longer duration of administration may have had a different ef-
fect. Male mice were used in this study, as the newly developed
model of sustained hind-limb ischaemia has not yet been tested
in female mice. It is important that future studies use female
mice as PAD is of equal burden in women30.
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